Abstract: Methods for diagnosis of neuroblastoma comprising determining whether there is a gain of genetic material from chromosome arm segment 17q21-qter in the circulating DNA of a human subject.
Abstract: The present invention relates to methods for determining the prognosis of a cancer. The methods involve determining the level of expression of the ZNF217 gene in a cancer cell sample or in a tumor sample wherein over-expression of ZNF217 is correlated with likelihood of metastasis and with likelihood of relapse/recurrence of the cancer.
Type:
Application
Filed:
July 19, 2010
Publication date:
May 3, 2012
Applicant:
CENTRE LEON BERARD
Inventors:
Pascale Cohen, Julie Vendrell, Pierre Roux
Abstract: The present invention relates to the treatment of cancer. More specifically, the present invention relates to the use of c-cbl as a marker for the diagnosis and/or prognosis of cancer, and to the use of a c-cbl antagonist for the treatment of a cancer associated with resistance to apoptosis.
Type:
Application
Filed:
February 10, 2010
Publication date:
March 29, 2012
Applicants:
Centre National De La Recherche Scientifique (C.N.R.S.), Centre Leon-Berard, Universite Claude Bernard Lyon 1
Inventors:
Daniel Regnier, Serge Manie, Sadok Yakoub, Eric Tabone
Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain, or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.
Type:
Application
Filed:
May 22, 2009
Publication date:
September 22, 2011
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTFIQUE (CNRS), CENTRE LEON BERARD, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
Inventors:
Patrick Etienne Roger Mehlen, Servane Marie-séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez
Abstract: The subject of the present invention concerns proteins with IL-6 inhibiting activity and thier use, and the use of proteins containing at least the amino acid seqeunce SEQ ID NO. 4 as medicianl product, in paritcular as anti-cancerous agent.
Type:
Grant
Filed:
December 4, 2002
Date of Patent:
August 19, 2008
Assignees:
Universite Claude Bernard Lyon 1, Centre Leon Berard, Institut National de la Sante et de la Recherche Medicale - I.N.S.E.R.M., Hospices Civils de Lyon